We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Immunoassay Developed for Rapid Leptospirosis Diagnosis

By LabMedica International staff writers
Posted on 13 Nov 2012
Print article
A rapid assay has been developed using immunodominant Leptospira immunoglobulin-like proteins in a Dual Path Platform (DPP) for the diagnosis of leptospirosis.

The rapid point-of-care immunoassay was evaluated for accuracy in diagnostic performance and compared with the microscopic agglutination test (MAT), in an urban setting.

Scientists at Duke University School of Medicine (Durham, NC, USA) and their collaborators measured the sensitivity of the assay using 446 serum samples from 378 individuals with either mild or severe leptospirosis from two urban Brazilian populations. Control sera, including healthy blood donors, dengue cases, and patients with confirmed syphilis were also tested.

The DPP assay for leptospirosis was developed by Chembio Diagnostic Systems (Medford, NY, USA) and is manufactured by Bio-Manguinhos (Rio de Janeiro, Brazil). The sera assayed by the DPP were also tested by an immunoglobulin M enzyme-linked immunosorbent assay (IgM- ELISA) and the MAT. Three independent operators visually interpreted results of the DPP after 20 minutes as either positive or negative.

The overall sensitivity for paired sera was 100% for severe and 73% for mild disease. In the acute phase of the infection, the assay achieved a sensitivity of 85% for severe and 64% for mild leptospirosis. Within seven days of illness onset, the assay achieved a sensitivity of 77% for severe disease and 60% for mild leptospirosis. Sensitivity of the DPP assay was similar to that for IgM-ELISA and increased with both duration of symptoms.

The authors concluded that the DPP assay performed acceptably well for diagnosis of severe acute clinical leptospirosis and can be easily implemented in hospitals and health posts where leptospirosis is a major public health problem. However, test accuracy may need improvement for mild disease and early stage leptospirosis, particularly in regions with high transmission. The study was published on November 1, 2012, in the journal Public Library of Science Neglected Tropical Diseases (PLoSNTD).

Related Links:

Duke University School of Medicine
Chembio Diagnostic Systems
Bio-Manguinhos


New
Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
Total 25-Hydroxyvitamin D₂ & D₃ Assay

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.